CompletedNCT00002485
Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer
Studying Extragonadal germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Oncology Group
- Principal Investigator
- Brad H. Pollock, PhD, MD PhDPediatric Oncology Group Statistical Office
- Intervention
- psychosocial assessment and care(procedure)
- Enrollment
- 359 enrolled
- Eligibility
- 21 years · All sexes
- Timeline
- 1992 – 2005
Study locations (30)
- University of California Davis Medical Center, Sacramento, California, United States
- Shands Hospital and Clinics, University of Florida, Gainesville, Florida, United States
- Sylvester Cancer Center, University of Miami, Miami, Florida, United States
- CCOP - Florida Pediatric, Tampa, Florida, United States
- Emory University Hospital - Atlanta, Atlanta, Georgia, United States
- Tripler Army Medical Center, Honolulu, Hawaii, United States
- CCOP - Wichita, Wichita, Kansas, United States
- MBCCOP - LSU Medical Center, New Orleans, Louisiana, United States
- Children's Hospital of Michigan, Detroit, Michigan, United States
- Hurley Medical Center, Flint, Michigan, United States
- Tomorrows Children's Institute, Hackensack, New Jersey, United States
- Mount Sinai School of Medicine, New York, New York, United States
- Memorial Mission Hospital, Asheville, North Carolina, United States
- Presbyterian Healthcare, Charlotte, North Carolina, United States
- East Carolina University School of Medicine, Greenville, North Carolina, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00002485 on ClinicalTrials.govOther trials for Extragonadal germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06418789High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell TumorsN.N. Petrov National Medical Research Center of Oncology
- RECRUITINGPHASE3NCT03067181Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell TumorsChildren's Oncology Group
- ACTIVE NOT RECRUITINGPHASE3NCT02375204Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell TumorsAlliance for Clinical Trials in Oncology